Physiopathology of intrauterine growth retardation: from classic data to metabolomics

Angelica Dessì1, Giovanni Ottonello, Vassilios Fanos

  • 1Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, AOU Cagliari, Italy.

Insights

Adverse intrauterine conditions, like intrauterine growth restriction (IUGR), permanently alter newborn metabolism, increasing adult disease risk. Metabolomics reveals these metabolic disruptions, aiding in early identification of neonatal disorders.

Area of Science:

  • Developmental biology
  • Neonatal medicine
  • Metabolomics

Background:

  • Intrauterine growth restriction (IUGR) and low birth weight are linked to adult chronic diseases, supporting the fetal origin of adult disease hypothesis.
  • Epidemiological studies demonstrate a correlation between low birth weight and the development of chronic pathologies later in life.

Purpose of the Study:

  • To review epidemiological evidence linking low birth weight to adult chronic diseases.
  • To explore metabolomics findings revealing altered metabolism in IUGR neonates.
  • To highlight the role of metabolomics in identifying neonatal metabolic disorders.

Main Methods:

  • Review of epidemiological studies correlating birth weight with adult health outcomes.
  • Analysis of metabolomics studies comparing metabolic profiles of IUGR infants and controls.
  • Examination of established and novel biomarkers for IUGR.

Main Results:

  • Epidemiological data confirm the association between low birth weight and increased risk of adult chronic diseases.
  • Metabolomics studies identify distinct metabolic alterations in newborns experiencing IUGR compared to healthy controls.
  • Metabolomics offers a comprehensive approach to understanding neonatal metabolic dysregulation.

Conclusions:

  • Adverse intrauterine conditions significantly impact neonatal physiology and metabolism, predisposing individuals to adult diseases.
  • Metabolomics is a powerful tool for identifying and understanding metabolic disorders in IUGR neonates.
  • Integrating metabolomics with traditional biomarkers enhances the identification of IUGR-related health risks.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Overview of Metabolism01:40

Overview of Metabolism

Living cells constantly carry out various chemical reactions which are necessary for their proper functioning. These reactions are interlinked to one another via multiple pathways. The collection of these chemical reactions is known as metabolism.
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...